These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
714 related articles for article (PubMed ID: 1324557)
1. Comparative contraceptive efficacy and mechanism of action of the norgestimate-containing triphasic oral contraceptive. London RS; Chapdelaine A; Upmalis D; Olson W; Smith J Acta Obstet Gynecol Scand Suppl; 1992; 156():9-14. PubMed ID: 1324557 [TBL] [Abstract][Full Text] [Related]
2. Selectivity and minimal androgenicity of norgestimate in monophasic and triphasic oral contraceptives. Anderson FD Acta Obstet Gynecol Scand Suppl; 1992; 156():15-21. PubMed ID: 1324552 [TBL] [Abstract][Full Text] [Related]
3. A comparison study of lipid and androgen metabolism with triphasic oral contraceptive formulations containing norgestimate or levonorgestrel. Janaud A; Rouffy J; Upmalis D; Dain MP Acta Obstet Gynecol Scand Suppl; 1992; 156():33-8. PubMed ID: 1324555 [TBL] [Abstract][Full Text] [Related]
4. Plasma hormone levels in women receiving new oral contraceptives containing ethinyl estradiol plus levonorgestrel or desogestrel. Gaspard UJ; Romus MA; Gillain D; Duvivier J; Demey-Ponsart E; Franchimont P Contraception; 1983 Jun; 27(6):577-90. PubMed ID: 6225622 [TBL] [Abstract][Full Text] [Related]
5. Preclinical evaluation of norgestimate, a progestin with minimal androgenic activity. Phillips A; Hahn DW; McGuire JL Am J Obstet Gynecol; 1992 Oct; 167(4 Pt 2):1191-6. PubMed ID: 1415445 [TBL] [Abstract][Full Text] [Related]
6. Ovarian function is effectively inhibited by a low-dose triphasic oral contraceptive containing ethinylestradiol and levonorgestrel. Gaspard UJ; Dubois M; Gillain D; Franchimont P; Duvivier J Contraception; 1984 Apr; 29(4):305-18. PubMed ID: 6430638 [TBL] [Abstract][Full Text] [Related]
7. Effect of two oral contraceptives containing ethinylestradiol and gestodene or norgestimate upon androgen parameters and serum binding proteins. Wiegratz I; Jung-Hoffmann C; Kuhl H Contraception; 1995 Jun; 51(6):341-6. PubMed ID: 7554973 [TBL] [Abstract][Full Text] [Related]
8. A randomized cross-over study on various hormonal parameters of two triphasic oral contraceptives. Aden U; Jung-Hoffmann C; Kuhl H Contraception; 1998 Aug; 58(2):75-81. PubMed ID: 9773261 [TBL] [Abstract][Full Text] [Related]
9. Serum levels of FSH, LH, estradiol-17 beta and progesterone following the administration of a combined oral contraceptive containing 20 micrograms ethinylestradiol. Carlström K; Lunell NO; Zador G Gynecol Obstet Invest; 1978; 9(6):304-11. PubMed ID: 754992 [TBL] [Abstract][Full Text] [Related]
10. Serum levels of d-norgestrel, luteinizing hormone, follicle-stimulating hormone, estradiol, and progesterone in women during and following ingestion of combination oral contraceptives containing dl-norgestrel. Brenner PF; Mishell DR; Stanczyk FZ; Goebelsmann U Am J Obstet Gynecol; 1977 Sep; 129(2):133-40. PubMed ID: 900174 [TBL] [Abstract][Full Text] [Related]
11. Evaluation of a new triphasic oral contraceptive in private practice. Ellsworth HS; Ayerst RI; Harris JW; Stone RA; Anderson AE; Jones TL; Curtis MK Contraception; 1986 Nov; 34(5):435-42. PubMed ID: 3102161 [TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of a monophasic and a triphasic oral contraceptive containing norgestimate. Corson SL Am J Obstet Gynecol; 1994 May; 170(5 Pt 2):1556-61. PubMed ID: 8178906 [TBL] [Abstract][Full Text] [Related]
13. Efficacy and clinical profile of a new oral contraceptive containing norgestimate. U.S. clinical trials. Corson SL Acta Obstet Gynecol Scand Suppl; 1990; 152():25-31. PubMed ID: 2189282 [TBL] [Abstract][Full Text] [Related]
14. A comparative randomized trial on the impact of two low-dose oral contraceptives on ovarian activity, cervical permeability, and endometrial receptivity. Rossmanith WG; Steffens D; Schramm G Contraception; 1997 Jul; 56(1):23-30. PubMed ID: 9306028 [TBL] [Abstract][Full Text] [Related]
15. The effect of extending the pill-free interval on follicular activity: triphasic norgestimate/35 micro g ethinyl estradiol versus monophasic levonorgestrel/20 micro g ethinyl estradiol. Creinin MD; Lippman JS; Eder SE; Godwin AJ; Olson W Contraception; 2002 Sep; 66(3):147-52. PubMed ID: 12384201 [TBL] [Abstract][Full Text] [Related]
16. A norgestimate-containing oral contraceptive: review of clinical studies. Kafrissen ME Am J Obstet Gynecol; 1992 Oct; 167(4 Pt 2):1196-202. PubMed ID: 1415446 [TBL] [Abstract][Full Text] [Related]
17. Serum lipid and lipoprotein changes induced by new oral contraceptives containing ethinylestradiol plus levonorgestrel or desogestrel. Gaspard UJ; Buret J; Gillain D; Romus MA; Lambotte R Contraception; 1985 Apr; 31(4):395-408. PubMed ID: 3159546 [TBL] [Abstract][Full Text] [Related]
18. Clinical evaluation of a new triphasic oral contraceptive: norgestimate and ethinyl estradiol. Gauthier A; Upmalis D; Dain MP Acta Obstet Gynecol Scand Suppl; 1992; 156():27-32. PubMed ID: 1324554 [TBL] [Abstract][Full Text] [Related]
19. A randomized cross-over comparison of two low-dose oral contraceptives upon hormonal and metabolic parameters: I. Effects upon sexual hormone levels. Kuhl H; Gahn G; Romberg G; März W; Taubert HD Contraception; 1985 Jun; 31(6):583-93. PubMed ID: 2931247 [TBL] [Abstract][Full Text] [Related]
20. Ovulatory dysfunction during continuous administration of low-dose levonorgestrel by subdermal implants. Faundes A; Brache V; Tejada AS; Cochon L; Alvarez-Sanchez F Fertil Steril; 1991 Jul; 56(1):27-31. PubMed ID: 1906017 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]